Recursion Pharmaceuticals reports Q3 EPS (35c), consensus (38c)

Reports Q3 revenue $13.2M, consensus $6.97M. Cash and cash equivalents were $454.6M as of September 30, which excludes proceeds from the private placement offering. "We are excited to have initiated four clinical trials in the past three quarters," said Chris Gibson, Co-Founder & CEO at Recursion. "In addition, our first clinical stage program discovered using our mapping and navigating approach to biology was nominated as a clinical stage program, with a Phase 2 clinical trial being planned now. We believe that our consistency in advancing our internal pipeline and transformational partnerships coupled with our willingness to continuously evolve our platform to more completely map and navigate biology and chemistry highlight Recursion as a leader within technology-enabled drug discovery."